APOLIPOPROTEIN-BASED LIPOPROTEIN SUBCLASS PROFILES AMP; VASC COMPLIC OF DIABETES

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。目的：研究糖尿病患者和对照者的载脂蛋白脂蛋白亚类谱及其与1型糖尿病患者糖尿病视网膜病变（DR）的相关性，以及他汀类药物对2型糖尿病患者的影响。原理：血管并发症是糖尿病发病率和死亡率的主要原因。有证据表明，血脂异常介导微血管和大血管并发症的风险。目前还没有关于1型糖尿病中载脂蛋白定义的脂蛋白亚类与DR相关的特征的报道，并且关于常用降脂药物对2型糖尿病亚类的影响的信息不足。由于基于载脂蛋白的颗粒分析允许复杂系统的新观点，该提议将提供重要的新知识。假设：基于载脂蛋白的血浆脂蛋白亚类谱与糖尿病大血管和微血管并发症的发生相关，并可能有助于识别血管并发症的高危患者。具体目标：在（目标1）50例1型糖尿病患者（25例DR，25例无DR）和对照受试者中确定基于载脂蛋白的脂蛋白谱，以确定与视网膜病变和糖尿病的相关性;以及（目标2）50例2型糖尿病患者（25例服用他汀类药物，25例未服用他汀类药物）和健康对照受试者，并确定与他汀类药物消耗的相关性。 目标3：研究1型和2型糖尿病受试者中基于载脂蛋白的谱与其他脂蛋白特征（NMR、apoA 1、B和Lp（a）、常规脂质谱）之间的关系。 方法：患者将从我们糖尿病诊所的患者队列中招募。载脂蛋白亚类测定和数据分析的所有方法均已到位。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Objectives: To investigate apolipoprotein-based lipoprotein subclass profiles in diabetic and control subjects and their associations with diabetic retinopathy (DR) in Type 1 diabetes and the effect of statins in Type 2 diabetes. Rationale: Vascular complications cause a majority of the morbidity and mortality of diabetes. Evidence suggests that dyslipidemia mediates risk for micro- and macro-vascular complications. There are no reports about the characterization of apolipoprotein-defined lipoprotein subclasses in Type 1 diabetes in relation to DR, and inadequate information about effects of commonly used lipid lowering drugs on subclasses in Type 2 diabetes. Since apolipoprotein-based particle analysis allows a new view of a complex system, this proposal will provide important new knowledge. Hypotheses: Apolipoprotein-based plasma lipoprotein subclass profiles are associated with the development of the macro- and micro-vascular complications of diabetes, and may help identify at-risk patients for vascular complications. Specific Aims: Determine apolipoprotein-based lipoprotein profile in (Aim 1) 50 type 1 diabetic patients (25 with DR, 25 without DR), and in control subjects to define associations with retinopathy and diabetes; and (Aim 2) in 50 type 2 diabetic patients (25 taking statins, 25 not taking statins), and healthy control subjects and to define associations with statin consumption. Aim 3: Investigate relationship between apolipoprotein-based profiles in type 1 and type 2 diabetic subjects and other lipoprotein characteristics (NMR, apoA1, B and Lp(a), conventional lipid profiles). Methods: Patients will be recruited from the patient cohort attending our diabetes clinics. All methods for apolipoprotein subclass determination and data analysis are in place.